Skip to main content
. 2022 Apr 18;14(8):2044. doi: 10.3390/cancers14082044

Figure 2.

Figure 2

(a) Scheme of HSA-ICG nanoparticles for enhanced tumor accumulation in 4T1 tumors by passive (EPR effect) and active (gp60 transcytosis pathway) targeting; (b) fluorescence imaging of 4T1 tumor-bearing mice after the injection of free ICG (upper) and HSA-ICG nanoparticles (lower) at different time intervals; (c) photoacoustic imaging of the mice; (d) tumor growth curves after different treatments (* p < 0.05, a: partial irradiation, b: accurate irradiation, c: over irradiation); (e) thermal images of mice exposed to 808 nm laser for 5 min. Figures are reproduced from ref. [58] with permission from the American Chemical Society.